---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-24-000114"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:37:11.516386+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Senti Bio Q3 net loss $28.9M; cash $10.5M; SENTI-202 data expected Q4 2024

## Summary
- Net loss $28.9M ($6.31 per share); R&D spend $8.7M (down from $9.1M YoY).
- Cash and equivalents $10.5M at Sept 30; subsequent $2.5M CIRM tranche received.
- Phase 1 enrollment of SENTI-202 ongoing; initial safety/efficacy data on track by year-end.
- CIRM grant total $8.0M; $4.9M received through Nov 2024.
- SENTI-301A pilot trial with Celest expects first patient dosing in Q4 2024.

## SEC filing metadata
- accession: 0001854270-24-000114
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/0001854270-24-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/snti-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-24-000114
- JSON: https://secwatch.observer/filing/0001854270-24-000114.json
- Plain text: https://secwatch.observer/filing/0001854270-24-000114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.